NEW YORK (GenomeWeb News) — NimbleGen will help Upstream Biosciences validate biomarkers, Upstream said today.
 
Under the agreement, NimbleGen will provide lab services including its whole-genome chromatin immunoprecipitation arrays to validate in silico binding-site predictions, Upstream said.
 
Upstream said it has filed five patents that would cover the use of genetic variations in certain regions that mark "various" cancers.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Congress approved a bill Friday that would increase the US National Institutes of Health's funding by $2 billion for fiscal year 2019.

UK's Labour Party calls for a ban on non-invasive prenatal testing for determining sex, BBC News reports.

Sarah Lawrence College's Laura Hercher warns in a New York Times op-ed that more people are going to need help figuring out what their consumer genetic testing results mean.

In PLOS this week: intra-tumor heterogeneity patterns, genomic analysis of Thoroughbred horse origins, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.